Pulmonary Hypertension : Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies
© 2024 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute..
Approved therapies for the treatment of patients with pulmonary arterial hypertension (PAH) mediate pulmonary vascular vasodilatation by targeting distinct biological pathways. International guidelines recommend that patients with an inadequate response to dual therapy with a phosphodiesterase type-5 inhibitor (PDE5i) and endothelin receptor antagonist (ERA), are recommended to either intensify oral therapy by adding a selective prostacyclin receptor (IP) agonist (selexipag), or switching from PDE5i to a soluble guanylate-cyclase stimulator (sGCS; riociguat). The clinical equipoise between these therapeutic choices provides the opportunity for evaluation of individualized therapeutic effects. Traditionally, invasive/hospital-based investigations are required to comprehensively assess disease severity and demonstrate treatment benefits. Regulatory-approved, minimally invasive monitors enable equivalent measurements to be obtained while patients are at home. In this 2 × 2 randomized crossover trial, patients with PAH established on guideline-recommended dual therapy and implanted with CardioMEMS™ (a wireless pulmonary artery sensor) and ConfirmRx™ (an insertable cardiac rhythm monitor), will receive ERA + sGCS, or PDEi + ERA + IP agonist. The study will evaluate clinical efficacy via established clinical investigations and remote monitoring technologies, with remote data relayed through regulatory-approved online clinical portals. The primary aim will be the change in right ventricular systolic volume measured by magnetic resonance imaging (MRI) from baseline to maximal tolerated dose with each therapy. Using data from MRI and other outcomes, including hemodynamics, physical activity, physiological measurements, quality of life, and side effect reporting, we will determine whether remote technology facilitates early evaluation of clinical efficacy, and investigate intra-patient efficacy of the two treatment approaches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Pulmonary circulation - 14(2024), 1 vom: 30. Jan., Seite e12337 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Varian, Frances [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Revised 20.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/pul2.12337 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369903838 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369903838 | ||
| 003 | DE-627 | ||
| 005 | 20240320234957.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240319s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/pul2.12337 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM369903838 | ||
| 035 | |a (NLM)38500737 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Varian, Frances |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pulmonary Hypertension |b Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. | ||
| 520 | |a Approved therapies for the treatment of patients with pulmonary arterial hypertension (PAH) mediate pulmonary vascular vasodilatation by targeting distinct biological pathways. International guidelines recommend that patients with an inadequate response to dual therapy with a phosphodiesterase type-5 inhibitor (PDE5i) and endothelin receptor antagonist (ERA), are recommended to either intensify oral therapy by adding a selective prostacyclin receptor (IP) agonist (selexipag), or switching from PDE5i to a soluble guanylate-cyclase stimulator (sGCS; riociguat). The clinical equipoise between these therapeutic choices provides the opportunity for evaluation of individualized therapeutic effects. Traditionally, invasive/hospital-based investigations are required to comprehensively assess disease severity and demonstrate treatment benefits. Regulatory-approved, minimally invasive monitors enable equivalent measurements to be obtained while patients are at home. In this 2 × 2 randomized crossover trial, patients with PAH established on guideline-recommended dual therapy and implanted with CardioMEMS™ (a wireless pulmonary artery sensor) and ConfirmRx™ (an insertable cardiac rhythm monitor), will receive ERA + sGCS, or PDEi + ERA + IP agonist. The study will evaluate clinical efficacy via established clinical investigations and remote monitoring technologies, with remote data relayed through regulatory-approved online clinical portals. The primary aim will be the change in right ventricular systolic volume measured by magnetic resonance imaging (MRI) from baseline to maximal tolerated dose with each therapy. Using data from MRI and other outcomes, including hemodynamics, physical activity, physiological measurements, quality of life, and side effect reporting, we will determine whether remote technology facilitates early evaluation of clinical efficacy, and investigate intra-patient efficacy of the two treatment approaches | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a oral prostacyclin‐receptor agonist | |
| 650 | 4 | |a remote monitoring | |
| 650 | 4 | |a soluble guanylate‐cyclase stimulator | |
| 650 | 4 | |a targeted therapy | |
| 700 | 1 | |a Dick, Jennifer |e verfasserin |4 aut | |
| 700 | 1 | |a Battersby, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Roman, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Ablott, Jenna |e verfasserin |4 aut | |
| 700 | 1 | |a Watson, Lisa |e verfasserin |4 aut | |
| 700 | 1 | |a Binmahfooz, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Zafar, Hamza |e verfasserin |4 aut | |
| 700 | 1 | |a Colgan, Gerry |e verfasserin |4 aut | |
| 700 | 1 | |a Cannon, John |e verfasserin |4 aut | |
| 700 | 1 | |a Suntharalingam, Jay |e verfasserin |4 aut | |
| 700 | 1 | |a Lordan, Jim |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Luke |e verfasserin |4 aut | |
| 700 | 1 | |a McCabe, Colm |e verfasserin |4 aut | |
| 700 | 1 | |a Wort, John |e verfasserin |4 aut | |
| 700 | 1 | |a Price, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Church, Colin |e verfasserin |4 aut | |
| 700 | 1 | |a Hamilton, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Armstrong, Iain |e verfasserin |4 aut | |
| 700 | 1 | |a Hameed, Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Hurdman, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Elliot, Charlie |e verfasserin |4 aut | |
| 700 | 1 | |a Condliffe, Robin |e verfasserin |4 aut | |
| 700 | 1 | |a Wilkins, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Webb, Alastair |e verfasserin |4 aut | |
| 700 | 1 | |a Adlam, David |e verfasserin |4 aut | |
| 700 | 1 | |a Benza, Ray L |e verfasserin |4 aut | |
| 700 | 1 | |a Rahimi, Kazem |e verfasserin |4 aut | |
| 700 | 1 | |a Shojaei-Shahrokhabadi, Mohadeseh |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Nan X |e verfasserin |4 aut | |
| 700 | 1 | |a Wason, James M S |e verfasserin |4 aut | |
| 700 | 1 | |a McIntosh, Alasdair |e verfasserin |4 aut | |
| 700 | 1 | |a McConnachie, Alex |e verfasserin |4 aut | |
| 700 | 1 | |a Middleton, Jennifer T |e verfasserin |4 aut | |
| 700 | 1 | |a Thompson, Roger |e verfasserin |4 aut | |
| 700 | 1 | |a Kiely, David G |e verfasserin |4 aut | |
| 700 | 1 | |a Toshner, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Rothman, Alexander |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pulmonary circulation |d 2011 |g 14(2024), 1 vom: 30. Jan., Seite e12337 |w (DE-627)NLM207988838 |x 2045-8932 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:30 |g month:01 |g pages:e12337 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/pul2.12337 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 30 |c 01 |h e12337 | ||